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1. Introduction  
Gene therapy is the process of treating a particular disease through the introduction of 
genetic material in order to elicit a therapeutic benefit [Stone, 2010]. The defective gene of a 
diagnosed patient can be corrected by a number of different strategies such as “gene 
replacement”, “gene correction”, and “gene augmentation” [Katare and Aeri, 2010]. In 
replacement therapy, a normal gene is inserted somewhere in the genome so that its product 
could replace that of a defective gene. This approach may be suitable for recessive disorders, 
which are marked by deficiency of an enzyme or other proteins. Although, the gene 
functions in the genome providing an appropriate regulatory sequence, the approach may 
not be successful in treating dominant disorders associated with the production of an 
abnormal gene product, which interferes with the product of normal gene [Katare and Aeri, 
2010]. Corrective gene therapy requires replacement of a mutant gene or a part of it with a 
normal sequence. This can be achieved by using recombinant technology. Another form of 
corrective therapy involves the suppression of a particular mutation by a transfer RNA that 
is introduced into a cell [Katare and Aeri, 2010]. In gene augmentation, introducing a normal 
genetic sequence into a host genome modifies the expression of mutant gene in defective cell 
and the defective host gene remains unaltered. In general, the gene therapy recipient cells 
may be germline cells or somatic cells. Germline cells therapy involves modifying the genes 
in germ cells which will pass these genetic changes to the future generations. Somatic cells 
therapy involves the insertion of genes into specific somatic cells like the bone marrow stem 
cells, fibroblasts, hepatocytes or mycocytes [Katare and Aeri, 2010]. This form of gene 
therapy is being used at most genetic engineering laboratories throughout the world.  
Clearly, gene therapy provides great opportunities for treating diseases from genetic 
disorders, infections and cancer [Park et al., 2006]. While the genetic mutations underlying 
various diseases are well understood, delivering a corrective gene to the unhealthy 
organs/tissues remains a remarkable challenge [Stone, 2010]. To achieve successful gene 
therapy, development of proper gene delivery systems could be one of the most important 
factors. Gene delivery systems should be designed to protect the genetic materials from 
premature degradation in systemic blood stream and to efficiently transfer the therapeutic 
genes to target cells. Intracellular delivery systems will be required for all molecules that 
have intracellular function. For example, nucleic acid molecules including encoding genes, 
oligonucleotides and RNA molecules must enter cells and target the nucleus when 
transcription is the target. Regardless of the molecules for delivery, a common requirement 
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is the avoidance of endosomal uptake that may cause degradation and denaturation [Gould 
and Chernajovsky, 2007]. Several approaches are being developed that can be applied to the 
delivery of all these types of molecules at disease sites. For the goal to be fully achieved, cell-
targeting strategies require still further development.  
Currently, a number of older and more recently discovered techniques have been developed 
for therapeutic gene transfer. A variety of viral and non-viral possibilities are available for 
basic and clinical researches [Gardlik et al., 2005]. Among these studies, DNA based 
vaccines are becoming popular. They stimulate the CD4+ T cells of Th1 subset and thereby 
mediate cellular immune response, which is effective against pathogens. On the other hand, 
the recombinant protein vaccines stimulate Th2 subset of T cells thereby eliciting a humoral 
response. The studies showed that DNA vaccines have been successful in protecting animals 
against influenza, herpes, rabies, malaria and leishmaniasis [Katare and Aeri, 2010]. 
However, the potential disadvantages of DNA vaccine have reduced the value of the 
approach. To optimize antigen delivery efficiency as well as vaccine efficacy, the non-viral 
vector as vaccine carrier has shown particular benefits to avoid the obstacles that both 
peptide/protein and gene-based vaccines have encountered [Chen and Huang, 2005]. For 
example, the success of the liposome-based vaccine has been demonstrated in clinical trials 
and further human trials are also in progress. This chapter summarizes the non-viral 
delivery routes and methods for gene transfer used in gene therapy and vaccine 
development. 
2. Gene delivery systems 
The simplest way of gene delivery is injecting naked DNA encoding the therapeutic protein, 
but because of low efficiency, there is a need to use special molecules and methods to 
improve gene delivery. A vector can be described as a system fulfilling several functions, 
including (a) enabling delivery of genes into the target cells and their nucleus, (b) providing 
protection from gene degradation, and (c) ensuring gene transcription in the cell. The ideal 
DNA vehicle should also be suitable for clinical application. It has to be inexpensive and 
easy to produce and purify in large amounts [Gardlik et al., 2005]. Two kinds of vectors 
have been employed as vehicles for gene transfer: 1) Viral vectors for gene transduction 
(e.g., retroviral, adenoviral, adeno-associated viral and lentiviral vectors), and 2) Non-viral 
vectors for gene transfection based on lipids, water soluble polycations, non-condensing 
polymers and nano/ micro-particles [Gardlik et al., 2005; Katare, 2010]. However, each 
vector has its own advantages and disadvantages.  
2.1 Viral vectors (biological delivery systems)   
Viral techniques use various classes of viruses as a tool for gene delivery [Gardlik et al., 
2005; Stone, 2010]. Viruses introduce their DNA into the cells with high efficiency. 
Therefore, it is possible to take advantage of this system by introducing a foreign gene into 
the virus and then using the properties of the virus to deliver this gene with high efficiency 
into the target cells [Gardlik et al., 2005]. Gene therapy vectors are being developed by 
genetic modification of retroviruses, adenoviruses, poxviruses, parvoviruses (adeno-associated 
viruses), herpesviruses etc. [Gardlik et al., 2005; Stone, 2010]. Unlike wild type viruses, these 
vectors are used to transfer therapeutic genes into target cells and thus are engineered by 
deleting the essential genes which allow replication, assembling or infection. Replication 
deficiency ensures the safety of viral vectors, but on the other hand, vectors need to be 
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produced in large amounts of virus particles. For this purpose, there are specialized cell 
lines called “packaging cell lines” (PCLs) engineered to replace a function of a deleted viral 
gene and for the production of recombinant viruses [Gardlik et al., 2005]. However, the 
interaction between a vector and a host-cell genome cannot be completely eliminated. Some 
disadvantages of viral delivery are addressed in Table 1.  
 
No. Disadvantage 
1 
Generation of an immune response to expressed viral proteins that subsequently 
kill the target cells producing a therapeutic gene product 
2 Random integration of some viral vectors into the host chromosome 
3 Clearance of viruses delivered systemically 
4 
Difficulties in engineering viral envelopes or capsids to achieve specific delivery to 
cells other than those with natural tropism for the virus 
5 
Possible recombination of the viral vector with DNA sequences in the host 
chromosome that generates a replication-competent, infectious virus 
6 Inability to administer certain viral vectors more than once 
7 High costs in producing large amounts of high-titer viral stocks for use in the clinic 
8 
Limited size of the nucleic acid that can be packaged and used for viral gene 
therapy 
Table 1. Viral delivery system disadvantages [Templeton and Lasic, 1999;  Gupta et al., 2004] 
Currently, developed Viruses as transfer vectors are divided into two classes, following 
their different strategies for replication and survival: a) Non-lytic viruses, including 
retroviruses and lentiviruses, produce virions from the cellular membrane of an infected cell, 
leaving the host cell relatively intact; b) Lytic viruses, including human adenovirus and herpes 
simplex virus families, destroy the infected cell after replication and virion production. This 
native nature of the original viruses determines the use of each recombinant replication-
defective viral vector in clinical applications [Table 2]. Despite some limitations on the use of 
viral vectors regarding safety and reproducibility, they are still the most used gene transfer 
vehicles [Gardlik et al., 2005; Katare, 2010; Gupta et al., 2004]. 
 
Vector Genome Structure Properties 
Adenoviruses dsDNA Capsid Transient expression, strong immunogenicity 
Alphaviruses RNA Envelope
Transient, but extreme, expression levels; low 
immunogenicity 
HSV dsDNA Envelope
Latent infection, long-term expression, low 
toxicity (mutant) 
Lentiviruses RNA Envelope
Genome integration, long term expression, 
safety concerns low titers, inefficient production 
Retroviruses RNA Envelope Genome integration, long-term expression 
Adeno-associated 
viruses (AAV) 
ssDNA Capsid 
Slow expression onset, genome integration, long 
term expression, inefficient large-scale virus 
production 
Table 2. Utilization of viral vectors for gene delivery [Katare and Aeri, 2010] 
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In clinical studies, a recombinant vaccinia virus vector has been developed to express 
single or multiple T cell co-stimulatory molecules as a vector for local gene therapy in 
patients with malignant melanoma. This approach generated local and systemic tumor 
immunity and induced effective clinical responses in patients with metastatic disease 
[Kim-Schulze and Kaufman, 2009]. Furthermore, PSA-TRICOM vaccine (prostate-specific 
antigen plus a TRIad of co-stimulatory molecules; PROSTVAC) includes a priming 
vaccination with recombinant vaccinia (rV)-PSA-TRICOM and booster vaccinations with 
recombinant fowlpox (rF)-PSA-TRICOM. Each vaccine consists of the transgenes for PSA, 
including an agonist epitope, and three immune co-stimulatory molecules (B7.1, ICAM-1, 
and LFA3; designated TRICOM) [Kaufman, 2002]. The efficacy of PSA-TRICOM has been 
evaluated in phase II clinical trials in patients with metastatic hormone-refractory prostate 
cancer (mHRPC). PANVAC-VF, another poxviral-based vaccine, consists of a priming 
vaccination with rV encoding CEA (6D), MUC1 (L93), and TRICOM plus booster 
vaccinations with rF expressing the identical transgenes. CEA (6D) and MUC1 (L93) 
represent carcinoembryonic antigen and mucin 1 glycoprotein, respectively, with a single 
amino acid substitution designed to enhance their immunogenicity. This vaccine  
is currently under evaluation in several different types of CEA or MUC1-expressing 
carcinomas and in patients with a life expectancy more than three months [Vergati et  
al., 2010].    
2.2 Non-viral vectors (Non-biological gene delivery systems)  
In comparison with virus-derived vectors, non-viral vectors have several advantages, such 
as the safety of administration without immunogenicity, almost unlimited transgene size 
and the possibility of repeated administration [Gardlik et al., 2005]. Non-viral gene delivery 
systems generally consist of three categories: (a) naked DNA delivery, (b) lipid-based and 
(c) polymer-based delivery [Park et al., 2006]. Therapeutic gene can be introduced into the 
target cell either as an insert in plasmid with regulation sequences, what enables the 
regulation control of expression (inducible promoter) or as a PCR product. The simplest 
way of gene introduction is an injection of naked DNA into target cells. Such a naked 
plasmid DNA was used in several pre-clinical and clinical trials [Gardlik et al., 2005]. For 
example, some positive results were gained in cancer therapy by intra-tumoral injection of 
tumor suppressor genes or cytokines. However, this approach does not have the 
transfection efficiency of viral vectors. Low transfection efficacy and short-term expression 
still remain the main disadvantages of naked DNA gene transfer compared with viral 
vectors. Thus, many techniques have been developed to improve the introduction of 
therapeutic gene. Physical methods like electroporation and gene gun increase the entry of 
transgene into target cells. In addition, chemical methods like lipoplexes (DNA-liposomes 
complexes) and polyplexes (DNA-polymers complexes) improve the stability of DNA and 
also facilitate the entry into the cell [Gardlik et al., 2005]. Main methods of gene delivering 
systems are summarized in figure 1.  
3. Physical delivery systems   
A number of methods utilizing various physical techniques have been developed  
to facilitate the transfer of foreign genes into the host cells [Katare and Aeri, 2010].  
Among them, electroporation and gene gun are further involved in preclinical and clinical 
trials. 
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Fig. 1. Summary of the main methods of gene delivery systems 
3.1 Electroporation   
One of the methods that improve DNA penetration of the cell is electroporation [Lee et al., 
2009; , Harrison et al., 1998; Rossini et al., 2002; Ahmad et al., 2009; Collins et al., 2006; Kang 
et al., 2011;]. In vivo use of electroporation is done by injecting naked DNA followed by 
electric pulses from electrodes that are located in situ in the target tissues. Successful use of 
electroporation was observed in transfecting muscles, brain, skin, liver, and tumors [Gardlik 
et al., 2005; Garcia-Frigola et al., 2007; Umeda et al., 2004; Babiuk et al., 2006; Harrison et al., 
1998; Kang et al., 2011]. Since every tissue is specific and has its own characteristics, there 
are no generally accepted optimal conditions of electroporation that are suitable for effective 
transfection. These are dependent both on the amplitude and duration of the electric pulses 
and on the amount and concentration of DNA [Gardlik et al., 2005]. The generated pulse 
may be either a high voltage (1.5 kV) rectangular wave pulse for a short duration or a low 
voltage (350 V) pulse for a longer duration [Katare and Aeri, 2010]. 
Up to now, several clinical trials have been planned using the electroporation with DNA 
vaccines for cancer therapy such as: a) Intra-tumoral IL-12 DNA plasmid (pDNA) [ID: 
NCT00323206, phase I clinical trials in patients with malignant melanoma]; 2) Intratumoral 
VCL-IM01 (encoding IL-2) [ID: NCT00223899; phase I clinical trials in patients with 
metastatic melanoma]; 3) Xenogeneic tyrosinase DNA vaccine [ID: NCT00471133, phase I 
clinical trials in patients with melanoma]; 4) VGX-3100 [ID: NCT00685412, phase I clinical 
trials for HPV infections], and 5) IM injection prostate-specific membrane antigen (PSMA)/ 
pDOM fusion gene [ID: UK-112, phase I/II clinical trials for prostate cancer] [Bodles-
Brakhop and Draghia-Akli, 2008; Bodles-Brakhop et al., 2009].   
Furthermore, Hepatitis C virus DNA vaccine showed acceptable safety when delivered by 
Inovio Biomedical's electroporation delivery system in phase I/II clinical study at 
Karolinska University Hospital. ChronVac-C is a therapeutic DNA vaccine being given to 
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individuals already infected with hepatitis C virus with the aim to clear the infection by 
boosting a cell-mediated immune response against the virus. This vaccination was among 
the first infectious disease DNA vaccine to be delivered in humans using electroporation-
based DNA delivery [Bodles-Brakhop et al., 2009].  
3.2 Gold bullet/gene gun  
Similar to electroporation, another method, called “gene-gun”, does not require the presence 
of complicated and potentially toxic delivery systems [Gardlik et al., 2005]. The gene 
transfer is mediated by small particles of gold on which the DNA is bounded. These 
particles are then shot into the cell under great pressure and speed (with the help of 
compressed helium) and so pass the membrane barrier [Katare and Aeri, 2010]. At first, the 
gene-gun was developed for gene transfer into plant cells; then, its use has expanded to 
gene transfer into the mammalian cells. Effective development of the gene-gun was also 
achieved in the field of DNA vaccination. The latest clinical experiments focus on cancer 
vaccines against various human tumors [Gardlik et al., 2005]. This method has been 
successfully used to deliver DNA in vivo into liver, skin, pancreas, muscle, spleen and 
tumors. Expression of reporter genes (e.g. firefly luciferase and ǃ- galactosidase) or 
therapeutic genes (human growth hormone) have also been reported by this method 
[Gardlik et al., 2005]. Recently, gene gun-mediated transgene delivery system has been used 
for skin vaccination against melanoma using tumor-associated antigen (TAA) human gpl00 
and reporter gene assays as experimental systems [Aravindaram and Yang, 2009 S]. In 
addition, the delivery of HPV DNA vaccines using intradermal administration through gene 
gun was shown to be the most efficient method of vaccine administration in comparison 
with routine intramuscular injection [Ogris and Wagner, 2002].  
Currently, a HPV16 DNA vaccine encoding a signal sequence linked to an attenuated form 
of HPV16 E7 (E7 detox) and fused to heat shock protein 70 [(Sig/E7detox/HSP70)] has been 
used in clinical trials. In a previous study, the immunologic and anti-tumor responses have 
been evaluated by the pNGVL4a-Sig/ E7 (detox)/ HSP70 vaccine administered using three 
different delivery methods including needle intramuscular, biojector and gene gun. 
According to obtained results, DNA vaccine administered via gene gun generated the 
highest number of E7-specific CD8+ T cells as compared to needle intramuscular and 
biojector administrations in mice model [Trimble et al., 2003].  
4. Chemical delivery systems   
In order to facilitate the effective transfer of non-viral DNA into the cells, synthetic vectors 
improving the DNA admission into the cell and protecting it from undesirable degradation 
were designed. The most chemical delivery systems were derived from lipids or synthetic 
polymers [Templeton and Lasic, 1999]. 
4.1 Lipoplexes (cationic lipids/liposomes)  
Plasmid DNA can be covered by lipids into organized structures such as liposomes or 
micelles [Templeton and Lasic, 1999]. The complex of DNA with lipids is called lipoplex. 
Lipoplexes can be divided into two types: 1) Anionic and neutral liposomes: At first, these 
kinds of lipids were used for the construction of synthetic vectors. Although, they were 
characterized by safety, compatibility with body fluids and the possibility of tissue-specific 
gene transfer, but the level of transduced cell expression was relatively low. At present, new 
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neutral and anionic liposomes suitable for in vivo gene therapy are being constructed 
[Gardlik et al., 2005; Gupta et al., 2004]; 2) Cationic liposomes: These lipids are naturally 
produced complexes with negatively charged DNA. Moreover, their positive charge allows 
interactions with the negatively charged cell membrane and thus penetration into the cell is 
permitted [Gardlik et al., 2005]. Cationic liposomes ensure effective protection against the 
degradation of the foreign DNA by the cell. The interactions of liposomes with DNA and the 
subsequent lipoplex formation are dependent on several physical conditions (pH, charge) as 
well as structural characteristics of the liposomes. The most frequent use of DNA-liposome 
complexes is in gene transfer into cancer cells, where the applied genes stimulate anti-tumor 
immune responses or genes decreasing the activity of oncogenes [Gardlik et al., 2005]. 
Recent studies revealed the ability of lipoplex gene transfer into the epithelial cells of the 
respiratory tract, which supports their usage in the therapy of respiratory diseases and 
cystic fibrosis. Their expression in all main organs, mostly in lungs, was observed after 
intravenous administration of lipoplexes. Targeted transfection can be gained, to some 
extent, by the addition of tissue-specific target ligand. It is suggested that the transfection is 
based on endocytosis of the host cell [Gardlik et al., 2005]. 
The advantages of using liposomes for gene therapy are included as: 1) lack of 
immunogenicity; 2) lack of clearance by complement system using improved formulations; 
3) unlimited size of nucleic acids that can be delivered, from single nucleotides up to large 
mammalian artificial chromosomes containing several thousand kilobases; 4) ability to 
perform repeated administrations in vivo without adverse consequences; 5) low cost and 
relative ease of generating nucleic acid: liposome complexes that deliver therapeutic gene 
products in large scale; 6) safety, because plasmids used for non-viral delivery contain no-
viral sequences, thereby precluding generation of an infectious virus; 7) naked DNA carried 
by liposome increases its uptake by antigen-presenting cells (APCs); 8) naked DNA carried 
by liposome enhances both humoral and cellular immunity; 9) naked DNA carried by 
liposome induces cytotoxic T lymphocyte response [Trimble et al., 2003]. 
For vaccine development, a general overview of different lipid-based particulate delivery 
systems, their composition, preparation methods, typical size, route of administration and 
model antigens has been listed by Myschik J. et al., 2009 [Myschik et al., 2009]. Stimuvax 
(BLP25 liposome vaccine, L-BLP25, Oncothyreon partnered with Merck KGaA) is a cancer 
vaccine designed to induce an immune response against the extracellular core peptide of 
MUC1, a type I membrane glycoprotein widely expressed on many tumors (i.e., lung cancer, 
breast cancer, prostate cancer and colorectal cancer) [Vergati et al., 2010]. Stimuvax consists 
of MUC1 lipopeptide BLP25 [STAPPAHGVTSAPDTRPAPGSTAPPK (Pal) G], an 
immunoadjuvant monophosphoryl lipid A, and three lipids (cholesterol, dimyristoyl 
phosphatidylglycerol, and dipalmitoyl phosphatidylcholine), capable of enhancing the 
delivery of the vaccine to APCs. A randomized phase II B clinical trial evaluated the effect of 
Stimuvax on survival and toxicity in 171 patients with stage III B and IV non-small cell lung 
cancer (NSCLC), after stable disease or response to first-line chemotherapy. Based on these 
data, Merck is currently conducting three large phase III clinical trials of Stimuvax. This 
study will involve more than 1300 patients [Vergati et al., 2010].  
Furthermore, a cationic lipid DNA complex (CLDC) consisting of DOTIM/cholesterol 
liposomes and plasmid DNA, containing immunostimulatory CpG and non-CpG motifs 
has been designed, with potential immunostimulating and anti-neoplastic activities. Upon 
systemic administration, TLR-directed cationic lipid-DNA complex JVRS-100 enters 
dendritic cells (DCs) and macrophages; immunostimulatory DNA binds to and activates 
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Toll-like receptors (TLRs), which may result in the generation of anti-tumor natural killer 
(NK) cell and T-cell responses by the innate immune system. In addition, as a vaccine 
adjuvant, this agent may induce a strong cytotoxic T-lymphocyte (CTL) response to  
co-administered antigen. The efficacy of JVRS-100 has been evaluated in phase I clinical 
trials for the treatment of patients with Relapsed or Refractory Leukemia [ID: 
NCT00860522]. 
4.2 Polyplex (polysaccharides/cationic polymers) 
A wide range of polymeric vectors have been utilized to deliver therapeutic genes in vivo. 
The modification of polymeric vectors has also shown successful improvements in achieving 
target-specific delivery and in promoting intracellular gene transfer efficiency [Park et al., 
2006, Ogris and Wagner, 2002]. Various systemic and cellular barriers, including serum 
proteins in blood stream, cell membrane, endosomal compartment and nuclear membrane, 
were successfully avoided by designing polymer carriers having a smart molecular structure 
[Park et al., 2006; Ogris and Wagner, 2002]. Vectors based on a complex of polymers with 
DNA are called polyplexes. Most of them consist of cationic polymers and their production 
is regulated by ionic interactions [Gardlik et al., 2005].  
In contrast to lipoplexes, some polyplexes (polylysin) are not able to release intracellular 
DNA into the cytoplasm [Gardlik et al., 2005]. For this purpose, co-transfection with 
endosome-lytic agents (inactivated adenovirus) is needed. On the other hand, polymers such 
as polyethylenimine have a mechanism of endosome disruption and there is thus no need 
for transfection with endosome-lytic agents. Polyethylenimine is used as a vector in aerosol 
inhalation gene therapy. It is a non-invasive and relatively effective gene transfer, especially 
into the respiratory tract, with permanent gene expression in this target region without 
undesirable expression in other tissues [Gardlik et al., 2005]. The size of the polymer 
determines the transfection efficiency and is specific for each individual gene transfer. 
Furthermore, the size of the aerosol particles determines the place of action, and thus the 
specificity of inhalation gene therapy [Gardlik et al., 2005]. An alternative to polyplexes can 
also be the use of polymer nanoparticles. Two types of such complexes have been 
characterized as gelatin-DNA and chitosan-DNA. In comparison with naked DNA, 
transfection using nanoparticles shows increased expression in vivo when administrated 
intratracheally or intramuscularly. Some polymeric vectors are summarized in the following 
sections:   
Poly (L-lysine) (PLL)-based gene delivery systems  
PLL has been widely used as a non-viral gene carrier since the formation of polyelectrolyte 
complexes between PLL and DNA was identified [Park et al., 2006]. Although, PLLs with 
high molecular weight have some properties suitable for a gene carrier, the PLL/DNA 
complexes showed a relatively high cytotoxicity and a tendency to aggregate and precipitate 
depending on the ionic strength. PEGylation [PEG: polyethylene glycol] of cationic 
polymers is known to greatly improve the problems of cytotoxicity, aggregation and non-
specific protein adsorption in vivo [Park et al., 2006]. Some examples are mentioned as 
following:  
• Sugar-conjugated PLL: Lactose and galactose have been used as conjugation partners 
with polymeric gene carriers for targeting asialoglycoprotein of hepatocytes. Lac-PEG-
PLL showed much less cytotoxicity and higher stability and solubility in a physiological 
condition compared to PLL [Park et al., 2006].  
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• Arterial-wall binding peptide (AWBP)-conjugated PLL: Arterial-wall binding peptide 
(AWBP) is a peptide containing the arterial-wall binding domain (1000-1016 amino 
acids) of apoB-100 protein, a major protein component of LDL. The AWBP was 
conjugated to PLL via a PEG linkage (AWBP-PEG-g-PLL). When interacted with a 
plasmid DNA, AWBP-PEG-g-PLL could form spherical shaped complexes with a size of 
100 nm and showed dramatic increase of transfection efficiency (150-180-fold), 
compared to PLL and PEG-g-PLL, in bovine aorta endothelial cells and smooth muscle 
cells. The presence of free AWBP in the transfection medium reduced the transfection 
efficiency of AWBP-PEG-g-PLL, suggesting that AWBP-PEG-g-PLL could be used as a 
tissue-selective gene carrier [Park et al., 2006].  
• Antibody-PLL conjugates: Antibody-antigen interaction is one of the most specific 
interactions in biological systems. A monoclonal antibody against leukemia-specific JL-
1 antigen (anti-JL-1-Ab) was conjugated with PLL by periodate-mediated oxidation of 
carbohydrate moiety in the Fc domain of the antibody, followed by reaction with PLL. 
The anti-JL-1-Ab-PLL conjugate demonstrated significantly higher transfection 
efficiency than PLL or lipofectin in leukemia (Molt 4) cells [Park et al., 2006].   
• Folate-conjugated PLL: Folate receptor has been identified as a potential target 
molecule of various cancer cells. The receptor is up-regulated and over-expressed in a 
number of rapidly growing malignant tumor cells, resulting in a dramatic promotion of 
the cellular uptake of folate. Therefore, the conjugation of folate to a variety of 
polymeric carriers has been chosen as a popular strategy for the target-specific delivery 
of anti-cancer therapeutics to the folate receptor-bearing tumor cells. A folate-PLL 
conjugate that incorporates a PEG spacer between folate and PLL (Fol-PEG-PLL) was 
also synthesized. The Fol-PEG-PLL was coated onto the complexes of PEI/DNA for a 
receptor-mediated gene transfer. The formulated complexes exhibited much higher 
transfection efficiency than PEI/DNA or lipofectamine/DNA complexes in the 
presence of 10% serum, suggesting that the PEG segment of Fol-PEG-PLL could 
increase the cellular uptake by receptor-mediated endocytosis and efficiently stabilize 
the complexes by increasing their solubility as well as by reducing the non-specific 
adsorption of serum proteins. The formulation also showed much lower cytotoxicity 
than PEI/DNA complexes [Park et al., 2006].  
• The Terplex system: The Terplex system is a low-density lipoprotein (LDL)-mediated 
targeting system, where the LDL specifically interacts with the LDL receptors on the 
cell surface. LDL receptors are membrane-anchored proteins present in many cell types 
including hepatocytes, endothelial cells and myocytes. The stearyl-PLL conjugate 
synthesized by N-alkylation of PLL with stearyl bromide interacts with a plasmid DNA 
to form complexes. The stearyl group could then bind to LDL via hydrophobic 
interaction to form the supramolecular gene carrier, the terplex. The Terplex system 
showed efficient in vitro transfection in a variety of cells including smooth muscle cells 
(A7R5), and human lung fibroblasts (CCD-32 Lu). The systemic administration of the 
Terplex system demonstrated prolonged circulation time compared to naked DNA 
[Park et al., 2006]. 
Polyethylenimine (PEI)-based gene carriers     
• PEI has been one of the most popularly employed cationic gene carriers due to its 
superior transfection efficiency in many different types of cells. The buffering property 
of PEI leads to protect the DNA from degradation in the endosomal compartment 
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during the maturation of the endosome to lysosome, facilitating intracellular trafficking 
of DNA. High cation density of PEI also contributes to the formation of highly 
condensed particles by interacting with DNA. However, the property may confer 
significant cytotoxicity. Studies with linear PEIs showed even higher transfection 
efficiency and lower cytotoxicity compared to branched PEI [Park et al., 2006]. There are 
different spectra utilizing PEI as described in following sections: 
• PEI-PEG: PEI-grafted PEGs (PEI-g-PEG) with different PEG grafting ratios were 
synthesized to address the cytotoxicity and aggregation problems of PEI. Cell 
cytotoxicity of PEI-g-PEG was greatly reduced, while the transfection efficiency of PEI-
g-PEG was still comparable to that of PEI. Cytotoxicity was independent of molecular 
weight of PEG but affected by the degree of PEG substitution [Park et al., 2006].  
• PEI conjugates with targeting moieties: a) PEI-g-PEG-RGD: An angiogenic endothelial 
cell targeted gene delivery system (PEI-g-PEG-RGD) was developed by incorporating 
the ǂνǃ3/ǂνǃ5 integrin binding RGD peptide. b) Antibody-conjugated PEIs: A 
monoclonal antibody against human epidermal growth factor receptor-2 (HER-2) was 
conjugated to linear PEI for targeted gene transfer to cancer cells. The HER-2 antibody-
PEI conjugate showed enhanced transfection efficiency in HER-2 over-expressing 
human breast adenocarcinoma cells (Sk-Br-3) compared to unmodified PEI [Park et al., 
2006]. 
• Folate-conjugated PEIs: Folate-polyethylene glycol-folate-grafted-polyethylenimine 
(FPF-g-PEI) was synthesized by grafting folate-PEG-folate to PEI. A PEI-PEG-folate 
(PEI-PEG-FOL) conjugate was used as a carrier for a plasmid encoding small interfering 
RNA (siRNA) targeting green fluorescence protein (GFP). The complexes between the 
PEI-PEG-FOL and the siRNA-expressing plasmid showed an efficient suppression of 
GFP expression compared to unmodified PEI complexes in folate receptor over-
expressing cells (KB), which stably expressed GFP [Park et al., 2006]. 
Water-soluble lipopolymer (WSLP): The water-soluble lipopolymer (WSLP) was 
synthesized by conjugating chlosteryl chloroformate to a low molecular weight PEI (1.8 
kDa). WSLP interacts with DNA to form stable colloidal particles (70 nm). The PEI moiety of 
WSLP confers a buffering effect, which could facilitate endosomal escape of the 
WSLP/DNA complex. It was also reported that the dodecylation of PEI enhanced the 
cellular uptake and transfection efficiency. In a similar way, the hydrophobic cholesterol 
moiety of WSLP would give a chance to form small and stable complexes, resulting in 
enhanced cellular uptake and transfection efficiency. WSLP showed higher transfection 
efficiency and much lower cytotoxicity than 25 kDa PEI, suggesting that WSLP has the 
advantages from PEI as well as from chlosterol. Intratumoral injection of 
WSLP/p2CMVmIL-12 complexes to tumor-bearing mice showed a significant improvement 
in the retardation of tumor growth and survival rate [Park et al., 2006].  
Biodegradable polycations  
The backbone linkages of most polymeric gene carriers consist of a –C-C- bond or amide 
bond, which are not degraded in physiological solutions. The non-degradable non-viral 
carriers are not easily removed by physiological clearance systems and therefore, can 
possibly accumulate within cells or tissues to elicit further cytotoxicity [Park et al., 2006]. To 
solve the problems, several biodegradable polycations have been synthesized and evaluated 
as potential gene carriers. Generally, the biodegradable polycations showed much less 
cytotoxicity and higher transfection efficiency compared to an unmodified polycations, such 
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as PLL or PEI [Park et al., 2006]. Some examples include: Poly (ǂ-[4-aminobutyl]-L-glycolic 
acid) (PAGA), a biodegradable PLL analogue; Poly(ǃ-amino ester)s; Poly(2-aminoethyl 
propylene phosphate) (PPE-EA); Degradable PEIs; The biodegradable PEIs were 
synthesized by crosslinking low molecular weight PEI (0.8 kDa) with either PEG-bis-
succinimidyl succinate or disulfide-containing cross-linkers, such as dithiobis 
(succinimidylpropionate) (DSP) and dimethyl 3,3’-dithiobispropionimidate (DTBP) [Park et 
al., 2006]. 
Neutral and non-condensing polymer-based gene delivery systems  
Although, cationic polymers, which electrostatically interact with DNA to neutralize its 
negative charge and condense DNA into nanosized particles, are generally considered as 
gene carriers, neutral polymers such as polyvinyl alcohol (PVA) and polyvinyl-pyrolidone 
(PVP) can also be used for gene transfer. They can protect DNA from enzymatic 
degradation and facilitate cellular uptake of DNA. These polymers may interact with DNA 
via hydrogen bonding and/or van der Waals interactions; van der Waals interaction of the 
hydrophobic vinyl backbones may cover around DNA to make its surface more 
hydrophobic. In a study, intramuscularly administered PVP/plasmid DNA formulation 
resulted in a significant increase in the number and distribution of the reporter-gene 
expressing cells in rat tibialis, compared to naked plasmid [Park et al., 2006]. 
5. Micro-/nano-particles 
Another approach to DNA-vaccine delivery involves microparticle-based technologies to 
target APCs [Ulmer et al., 2006]. Microencapsulation of DNA, or association of DNA with 
microcapsules, has led to enhancement of CTL responses to encoded proteins [Doria-Rose 
and Haigwood, 2003]. Biodegradable, non-antigenic poly-lactide polyglycolide (PLGA or 
PLG) microspheres offer many advantages as a vaccine delivery system. Both cellular and 
humoral immune responses can be elicited to antigens encapsulated in, or conjugated onto 
PLG microspheres. Particles used typically range in size from 1 to 10 µm in diameter, a size 
that is readily phagocytosed by dendritic cells and other antigen-presenting cells (APCs). 
Microspheres elicit both CD8+ and CD4+ T cell responses by releasing antigen 
intracellularly [Doria-Rose and Haigwood, 2003]. Biodegradable PLGA nanoparticles (NPs) 
have been investigated for sustained and targeted/localized delivery of different agents, 
including drugs, proteins and peptides and recently, plasmid DNA owing to their ability to 
protect DNA from degradation in endolysosomes. PLGA-based nanotechnology has been 
widely used in diagnosis and treatment of cancer. These NPs have been shown to stimulate 
the immune response as measured by an increase in IL-2 and IFN-γ in spleen homogenates 
[Lu et al., 2009]. The majority of the existing literature involving PLGA polymers has tended 
to be focused on PLGA microspheres. In the last 10 years, microspheres have been used 
extensively for the injectable delivery of vaccine antigens, both for viral and bacterial 
antigens. Similar to microspheres, PLGA NPs have been shown to effectively enhance 
immune responses. The major obstacle is providing delivery vehicles with the adequate 
surface molecules for recognition by the immune system and for more effective targeting. It 
is likely, therefore, that future studies of PLGA NPs as vaccine candidates will focus on 
improving these features, as recently tested by grafting RGD peptides (arginine–glycine–
aspartic acid-containing synthetic peptides) covalently onto PEG moieties on the surface of 
PLGA NPs [Lu et al., 2009].  
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These polymers have been designated as feasible candidates for drug delivery systems, anti-
cancer agents and vaccine immunotherapy. For example, DNA vaccine delivery to APCs has 
been facilitated by microencapsulation of plasmid DNA, which encodes HPV E6/E7 
antigenic proteins. The capsule is formed from polymeric PGLA microparticles. These 
resulting microparticles have a greater propensity toward APC uptake compared to naked 
DNA. This technique allows HPV DNA plasmid to be condensed inside the microparticle. 
The physical and chemical properties of the PGLA scaffold make DNA inaccessible to 
nuclease and preventing degradation, allowing for a sustained release of DNA and 
enhancing transfection efficiency in vitro [Lin et al., 2010]. In mice, microspheres containing 
HPV plasmid encoding HPV E6/E7 antigens have been shown to elicit a strong antigen-
specific cytotoxic T cell response. Using this technology, microencapsulated DNA vaccine 
termed ZYC-101 encoding multiple HLA-A2 restricted HPV E7 epitopes has undergone 
Phase I trials in patients with CIN2/3 lesions and high-grade anal intraepithelial neoplasia. 
In both trials, intramuscularly administered vaccine was well tolerated, and in some patients 
had resulted in histological regression of the lesions as well as generation of E7-specific IFN-
γ expressing T cells. A newer version of the DNA vaccine, ZYC-101a, which encodes HPV16 
and HPV18 E6- and E7-derived epitopes has been used in phase II clinical trial in patients 
with CIN 2/3 lesions [Lin et al., 2010]. 
The multi-functional nano-devices based on the dendritic polymer or dendrimers are also 
being applied to a variety of cancer therapies to improve their safety and efficacy. Technical 
advances have been focused on the development of a linking strategy that allows the 
dendrimer molecules to be linked via complementary oligonucleotides. At present, further 
applications of dendrimers in photodynamic therapy, boron neutron capture therapy, and 
gene therapy for cancer are being examined [Baker, 2009].  
Recently, the modified fluorescent nanoparticles have been synthesized as a targeting and 
delivery system, by conjugating both tumor targeting agent and chemokines to the 
nanoparticles, in order to attract immune cells toward tumor cells. Biodegradable chitosan  
nanoparticles encapsulating quantum dots were prepared, with suitable surface 
modification to immobilize both tumor targeting agent and chemokine on their surfaces 
[Chatterjee and Zhang, 2007]. Fluorescent chitosan coated quantum dots (QDs) were used to 
act as bi-functional bridging units between cancer and immune cells. This nanoparticulate 
form of delivery promises the advantages of enhanced tumor selectivity and longer half-
lives, thereby enhancing effectiveness of the immune response and reduction in systemic 
toxicity [Chatterjee and Zhang, 2007]. Furthermore, the rapid development of Quantum 
Dots (QDs) technology has already fulfilled some of the hopes of developing new, more 
effective cancer-imaging probes. First, stable encapsulation of QDs with amphiphilic 
polymers has prevented the quenching of QD fluorescence in the aqueous in vivo 
environment. Second, QDs are relatively inert and stable. Finally, successful conjugation of 
QDs with biomolecules has probably made active targeting them to tumors. Despite their 
success so far in cancer imaging, there are challenges in enhancing sensitivity, maximizing 
specificity and minimizing toxicity of QDs, which must be undertaken before clinical 
applications can proceed [Zhang et al., 2008]. A major parameter limiting immune responses 
to vaccination is the number of activated APCs that capture antigen and migrate to draining 
lymph nodes. The use of cellular magnetic resonance imaging (MRI) is a promising 
approach for this purpose [Long et al., 2009]. In a study, an in vivo labeling method was 
described, which relies upon cell-to-cell transfer of super-paramagnetic iron oxide (SPIO) 
from tumor cells to endogenous APCs, in situ, for quantification of APC delivery to lymph 
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nodes in a tumor vaccine model. Mice were immunized with a tumor cell–based vaccine that 
was labeled with SPIO. APCs that had captured SPIO were imaged over time as they 
accumulated in lymph nodes. It was indicated that MRI is capable of monitoring, in vivo, the 
trafficking of magnetically labeled APCs inducing a tumor-specific immune response, and 
that these cells can be magnetically recovered ex vivo. Excellent correlation was observed 
between in vivo and ex vivo quantification of APCs, with resolution sufficient to detect 
increased APC trafficking elicited by an adjuvant [Long et al., 2009].  
6. Cationic peptides/cell-penetrating peptides (CPP)/trojan peptides 
The studies have shown that a number of peptides and proteins are able to penetrate the cell 
membrane and enter the cell. It has been observed that many cargo molecules that are 
covalently attached to these peptides will be translocated into the cell. Recently, various 
natural and/ or synthetic cell-penetrating peptides (CPP) have known as efficient tools in 
vaccine design as they are capable of delivering therapeutic targets into cellular 
compartments. In fact, the cell membrane is impermeable to hydrophilic substances and 
delivery into cells could be facilitated by linking to CPP. Different cargos such as drugs, 
peptide/ protein, oligonucleotide/ DNA/ RNA, nanoparticles, liposomes, bacteriophages, 
fluorescent dyes and quantum dots have been linked to CPPs for intracellular delivery with 
possible use in future vaccine design [Brooks et al., 2010]. Two applications of CPP already 
validated in vaccine studies are delivery of tumor-associated antigens into antigen-
presenting cells (APCs) and use as a non-viral gene delivery vehicle in DNA vaccines. There 
are two methods for designing CPP incorporating immunogenic antigens: A) chemical 
linking via covalent bonds B) coupling via recombinant fusion constructs produced by 
bacterial expression vectors. The orientation of the peptide and cargo and the type of linkage 
are likely important [Brooks et al., 2010]. In addition, the utilized CPP, attached cargo, 
concentration and cell type, all significantly affect the mechanism of internalization. The 
mechanism of cellular uptake and subsequent processing still remains controversial. It is 
now apparent that CPP mediate intracellular delivery via both endocytic and non-endocytic 
pathways [Brooks et al., 2010; Jarver and Langel, 2004; Wagstaff and Jans, 2006]. An 
attractive feature of using polypeptides as gene delivery vectors is incorporating multiple 
functional domains into one polypeptide chain, such as a DNA-binding domain linked with 
a receptor-targeting domain. This kind of polypeptides will recognize and bind to cell 
surface receptors that are unique to target cells and deliver the bound DNA into the cells 
through receptor-mediated endocytosis. Therefore, this process may ensure the therapeutic 
effect in desired cells and limit the potential side effects caused by transgene expression into 
the non-targeted cells [Zeng and Wang, 2005].  
Several studies have shown that oligo-deoxynucleotides (ODN) with immune-stimulating 
sequences (ISS) containing CpG motifs facilitate the priming of MHC class I- restricted 
CD8+ T cell responses to proteins or peptides. Therefore, ODN/cationic peptide complexes 
are potent tools for priming CD8+ T cell immunity [Schirmbeck et al., 2003]. The complex 
formation required electrostatic linkage of the positively charged peptide to the negatively 
charged ODN. Conjugation of immunostimulatory DNA or ODN to protein antigens 
facilitates the rapid, long-lasting, and potent induction of cell-mediated immunity. It was 
shown that ODN (with or without CpG-containing sequences) are potent Th1-promoting 
adjuvants when bound to cationic peptides covalently linked to antigenic epitopes, a mode 
of antigen delivery existing in many viral nucleocapsids [Schirmbeck et al., 2003]. Table 3 
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contains a list of peptides that have been investigated for their ability to penetrate the cell 
[Futaki, 2005; Brooks et al., 2010]. 
 
Class Protein 
Functional 
peptide
Sequence 
Translocation 
efficiency 
Reference 
Basic TAT  [HIV] 
Tat and related 
peptides 
  
Vives et 
al., 1997 
  HIV-1 Tat (48-60) GRKKRRQRRRPPQ +++ 
Futaki, 
2005; 
Brooks et 
al., 2010 
  R9-Tat GRRRRRRRRRPPQ +++ 
Futaki, 
2005 
Basic  
Arginine-rich 
RNA binding 
peptides 
  
Futaki, 
2005; 
Brooks et 
al., 2010 
  HIV-1 Rev-(34-50) TRQARRNRRRRWRERQR +++ 
Futaki, 
2005 
  R7W Fluo-RRRRRRRW-NH2 +++ 
Futaki, 
2005 
  TatP59W 
Fluo-
GRKKRRQRRRPWQ-NH2
+++ 
Futaki, 
2005 
  FHV Coat-(35-49) RRRRNRTRRNRRRVR  
Futaki, 
2005 
  BMV Gag-(7-25) 
KMTRAQRRAAARRNR
WTAR
+++ 
Futaki, 
2005 
  
HTLV-II REX-(4-
16)
TRRQRTRRARRNR +++ 
Futaki, 
2005 
  CCMV Gag-(7-25)
KLTRAQRRAAARKNKR
NTR
++ 
Futaki, 
2005 
  P22 N-(14-30) NAKTRRHERRRKLAIER ++ 
Futaki, 
2005 
Basic VP22 [HSV] VP22 
DAATATRGRSAASRPTE
RPRAPARSASRPRRPVE
+++ 
Cashman 
et al., 2002 
 
Human 
Calcitonin 
hCT (9-32) 
LGTYTQDFNKFHTFPQT
AIGVGAP
 
Trehin et 
al., 2004 
 
Vascular 
endothelial 
cadherin 
[Mouse]
pVEC LLIILRRRIRKQAHAHSK  
Elmquist 
et al., 2001 
 
Related to γ-
Zein [Maize] 
Sweet arrow 
peptide (SAP) 
(VRLPPP)3  
Fernandez
-Carneado 
et al., 2004 
 
Related to γ-
Zein [Maize] 
 (Tyr-ZnDPA)n  
Johnson et 
al., 2008 
Basic/ 
amphiph-
ilic 
Antennapedia 
homeodomain 
[Drosophila] 
Antennapedia 
(43-58) 
[penetratin]
RQIKIWFQNRRMKWKK +++ 
Derossi et 
al., 1994 
  Fluoro-Penetratin
Fluo-
RQIKIWFQNRRMKWKK
-NH2
 
Futaki, 
2005 
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  Pen2W2F 
Fluo-
RQIKIFFQNRRMKFKK-
NH2 
 
Futaki, 
2005 
  
Model 
amphipathic 
peptide 
KLALKLALKALKAALKL
A-NH2 
 
Futaki, 
2005 
  PenArg 
Fluo-
RQIRIWFQNRRMRWRR-
NH2 
 
Futaki, 
2005 
  PenLys 
Fluo-
KQIKIWFQNKKMKWKK
-NH2 
 
Futaki, 
2005 
  E N-(1-22) 
MDAQTRRRERRAEKQA
QWKAAN 
+ 
Futaki, 
2005 
  B21 N-(12-29) 
TAKTRYKARRAELIAER
R 
+ 
Futaki, 
2005 
  
Yeast PRP6-(129-
144) 
TRRNKRNRIQEQLNRK + 
Futaki, 
2005 
  
Hum U2AF-(142-
153) 
SQMTRQARRLYV - 
Futaki, 
2005 
Chimera 
(synthetic) 
Galanin/ 
Mastoparan) 
Transportan 
GWTLNSAGYLLGKINLK
ALAALAKKIL 
 
Pooga et 
al., 1998 
 
Galanin/ 
Mastoparan) 
Model 
amphipathic 
peptide (MAP) 
KLALKLALKALKAALKL
A amide 
 
Oehlke et 
al., 1998 
 
Hydrophobic-
NLS 
Pep-1 
KETWWETWWTEWSQP
KKKRKV 
 
Morris et 
al., 2001 
 
Hydrophobic-
NLS 
CADY 
Ac-
GLWRALWRLLRSLWRL
LWRA-cysteamide 
 
Crombez 
et al., 2009 
 
Hydrophobic- 
NLS 
Membrane 
translocating 
sequence peptide 
(MTS) 
AAVALLPAVLLALLP  
Rojas et 
al., 2008 
 
HIVGp41-NLS 
of SV40  
T-antigen 
MPG 
GALFLGWLGAAGSTMG
APKKKRKV 
 
Morris et 
al., 2008 
Table 3. Protein transduction domains (PTD) 
Furthermore, the HIV Tat derived peptide is a small basic peptide that has been successfully 
shown to deliver a large variety of cargoes, from small particles to proteins, peptides and 
nucleic acids. The “transduction domain” or region conveying the cell penetrating 
properties is clearly confined to a small stretch of basic amino acids, with the sequence 
RKKRRQRRR (residues 49–57) [Riedl et al., 2004; Brooks et al., 2005]. This polycationic 
nanopeptide is known to be a transfection enhancer of plasmid DNA. The conditions of 
DNA-peptide complex formation and DNA/Tat ratio have significant impact on the level of 
transgene expression and degree of DNA protection from nuclease attack [Hellgren et al., 
2004]. The conjugation of this peptide to ovalbumin (OVA) resulted in efficient stimulation 
of MHC class I-restricted T cell responses in vitro and, more importantly, the generation of 
CTLs in vivo [Kim et al., 1997]. Also, soluble Tat-antigen conjugates can deliver the antigen 
directly to the MHC class I processing pathway and thereby increase the generation of 
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antigen-specific CD8+ T cells in vitro [Kim et al., 1997; Riedl et al., 2004]. A fusion protein 
containing the carboxy-terminal end of Tat (amino acids: 49–86) linked to the HPV16 E7 
oncoprotein enhanced tumor specific immune responses in vivo [Giannouli et al., 2003]. In 
C57BL/6 mice, E7-Tat mixed with Quil A generated efficient prophylactic and therapeutic 
suppression of HPV16-positive C3 tumor outgrowth. This study offers a new strategy for 
improving subunit cancer vaccines [Giannouli et al., 2003]. Particularly, a Tat-derived 
peptide in combination with a PEG-PEI copolymer could be a promising candidate as gene 
delivery vehicle intended for pulmonary administration. Tat-PEG-PEI represents a new 
approach to non-viral gene carrier for lung therapy, comprising protection for plasmid 
DNA, low toxicity and significantly enhanced transfection efficiency under in vivo 
conditions [Kleemann et al., 2005].  
It has been shown that covalent attachment of low molecular weight polyethyleneimine 
(PEI) improves Tat peptide mediated gene delivery in vitro [Alexis et al., 2006; Putnam et al., 
2001; Wang, 2006]. In our recent study, two delivery systems including polymer PEI 25 kDa 
and polymer peptide hybrid as PEI600-Tat conjugate were used to compare their efficiency 
for HPV16 E7 DNA transfection in vitro. Our data indicated that both delivery systems 
including PEI 25 kDa and PEI600-Tat conjugate are efficient tools for E7 gene transfection. In 
fact, PEI potency for E7 gene transfection is higher than PEI600-Tat in vitro, but its toxicity is 
obstacle in vivo [Bolhassani et al., 2008]. Using HPV16 E7 as a model antigen, the effect of 
PEI600-Tat conjugate has been evaluated on the potency of antigen-specific immunity in 
mice model. Assessment of lymphoproliferative and cytokine responses against 
recombinant E7 protein (rE7) showed that PEI600-Tat/E7DNA complex at certain ratio 
induces Th1 response. This study has demonstrated that PEI600-Tat conjugate is efficient to 
improve immune responses in vivo [Bolhassani et al., 2009]. 
Moreover, synthetic peptides containing a nuclear localization signal (NLS) can be bound to 
the DNA and the resulting DNA-NLS complexes can be recognized as a nuclear import 
substrate by specific intracellular receptor proteins [53]. For example, conjugation of an NLS 
to a Minimalistic Immunogenically Defined Gene Expression (MIDGE) vector encoding a 
truncated and secreted form of BHV-1 glycoprotein D (tgD) improved the tgD expression in 
vitro and induced both humoral and cellular immune responses in mice [Zheng et al., 2006]. 
This strategy could be applied as an efficient pathway in enhancement of DNA vaccine 
potency against cancer. 
On the other hand, one of the CPPs that have currently received extensive attention in the 
field of DNA vaccination is the herpes simplex virus (HSV-1) protein VP22 [Brooks et al., 
2010]. VP22 can form compacted complexes with short oligonucleotides and form 
particles of spherical nature with a size range of 0.3 to 1 µm in diameter. These particles 
entered cells efficiently within 2 to 4 hours. Furthermore, VP22 enables spreading of the 
antigenic peptide to the cells surrounding the transfected cells [Brooks et al., 2010]. Efforts 
have been made to increase the potency of DNA vaccines by exploiting the cell-to-cell 
spreading capabilities of the HSV-1 VP22 protein or the analogous protein from bovin 
herpesvirus 1 [Ulmer et al., 2006]. The significance of VP22 in intercellular spreading has 
been demonstrated through in vitro studies linking VP22 to p53, thymidine kinase, 
cytosine deaminase and Green Fluorescent Protein (GFP). These proteins were observed 
to be distributed to nuclei of surrounding cells [Lin et al., 2010]. Furthermore, vaccination 
with DNA encoding HPV16E7 linked to the HSV type 1 VP22 elicited the enhanced E7-
specific memory CD8+ T lymphocytes and anti-tumor effects against E7-expressing tumor 
cells [Michel et al., 2002]. Also, VP22 has been used for HPV DNA vaccines targeting the 
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E6 protein [Lin et al., 2010]. Various groups have demonstrated that DNA constructs 
which encode fusion proteins of VP22 linked to an antigen increase the immune responses 
in mice and cattle. Bovine herpesvirus VP22 (BVP22) and Marek’s disease virus VP22 
(MVP-1) are both closely related by their structural homology to HSV-1 VP22, and can 
also have a significant role in intercellular spreading. Hung et al. has demonstrated that 
mice vaccinated with DNA encoding MVP22/E7 significantly increased numbers of IFN-
γ-secreting, E7-specific CD8+ T cell precursors compared to mice vaccinated with wild-
type E7 DNA alone, which directly lead to a stronger tumor prevention response. 
Similarly, immunization of mice and cattle with DNA vaccine coding for BVP22 linked to 
truncated glycoprotein D (BVP-tgD) was shown to generate a stronger tgD-specific 
immune response compared to animals vaccinated with tgD alone. Taken together, DNA 
vaccine encoding VP22 linked to antigens represents a promising approach to enhance 
DNA vaccine potency [Lin et al., 2010].  
To evaluate the VP22 role in gene therapy of hepatocellular carcinomas (HCCs), the 
expression vectors were constructed for N- and C-terminal fragments of VP22-p53 fusion 
proteins and investigated the VP22-mediated shuttle effect in hepatoma cells by co-
transfection experiments. VP22-mediated trafficking was not detectable in hepatoma cells 
in vitro by fluorescence microscopy [Zender et al., 2002]. For in vivo experiments, the 
recombinant adenoviruses Ad5CMVp53 and Ad5CMVp53-VP22 were constructed. In 
contrast to the in vitro experiments, intercellular trafficking of VP22-p53 could be 
observed in subcutaneous tumors of hepatoma cells by fluorescence microscopy, 
indicating a stronger shuttle effect in solid tumors compared to cell culture experiments 
[Zender et al., 2002]. In our current study, Herpes simplex virus type 1 (HSV-1) VP22 
protein was employed to enhance DNA vaccine potency of Leishmania major amastin 
antigen in BALB/c mice model. Vaccination with the VP22-amastin-EGFP fusion 
construct elicited significantly higher IFN-gamma response upon antigen stimulation of 
splenocytes from immunized mice compared to amastin as a sole antigen. These results 
suggest that the development of DNA vaccines encoding VP22 fused to a target 
Leishmania antigen would be a promising strategy to improve immunogenicity and DNA 
vaccine potency [Bolhassani et al., 2011]. 
7. Hybrid vectors  
A promising approach to overcome the limitations and develop the advantages of the 
individual types of vectors is their combination. Several types of hybrid vectors have been 
known: A) Virosomes are produced by the fusion of lipoplexes (liposomes with DNA) with 
inactivated HVJ virus (hemagglutinating virus of Japan) or influenza virus [Gardlik et al., 
2005]. It was shown that the efficiency of gene transfer into the respiratory tract is higher 
than cationic liposomes or viral vectors. In addition, they are very well tolerated from the 
immunological view, so even repeated injection does not influence the efficiency and safety 
of transfer; B) The second type is represented by hybrids that were generated by mixing 
cationic liposomes or polymers with adenoviral vector. These are effective mainly in cells 
which do not have viral receptors. In addition,  it was proved that an inactivated adenovirus 
attachment improves the efficiency of the transfer mediated by cationic liposomes or 
polymers [Gardlik et al., 2005]; C) Hybrid viruses can be produced by a combination of 
various types of viral vectors, and they represent a system which employs the main 
advantages of both viruses [Gardlik et al., 2005].  
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8. Bacterial delivery systems   
The most recent approach in targeting the gene therapy is the use of bacterial systems as 
vectors for transfer and gene expression in tumor cells. The principle lies in the ability of some 
anaerobic bacteria to selectively colonize hypoxic areas (e.g., tumors) and replicate there. 
Therefore, it is possible to achieve selective expression of therapeutic genes specifically in 
tumors. Currently known and tested bacterial vectors have been divided into two groups: A) 
Strictly anaerobic bacteria (the species Clostridium and Bifi dobacterium) are used in in vivo 
experiments. Clostridium is the most important bacterial species for use as a vector. On the 
other hand, the non-pathogenic Bifi dobacterium, is naturally present in the human 
gastrointestinal tract and provides higher safety [Gardlik et al., 2005]. B) The second group 
consists of attenuated auxotrophic strains of Salmonella typhimurium that require the presence 
of tumor specific nutrition factors for selective replication. They use these factors for their own 
metabolism, thus prohibiting the tumor cells from utilizing them and growing. In in vivo 
experiments, high levels of Salmonella (109 bacteria/g tissue) were obtained. A similar tumor 
inhibitory effect was shown by application of Salmonella producing tymidin-kinase [Gardlik et 
al., 2005]. Although the above bacteria are characterized by high selectivity in tissue 
colonization, it is necessary to ensure the maximum level of specificity and therapeutic 
efficiency of bacterial vectors. For this purpose, promoters inducible by radiation were 
constructed. The transcription of such promoters is conditioned by irradiation with visible 
light. Bacteria are known for their resistance to irradiation (having a relatively small genome 
and effective DNA repair mechanisms). Therefore the localization of a therapeutic gene under 
the control of a radiation-inducible promoter ensures that cytotoxic proteins are expressed 
only in bacteria colonizing currently irradiated tissues. This strategy allows eliminating the 
possibility of expression in non-tumor and hypoxic tissues. The latest approach using 
prokaryotes in gene therapy is a system of transformed bacteria producing a therapeutic 
protein in situ under exogenous induction regulation [Gardlik et al., 2005]. 
9. Eukaryotic delivery systems 
9.1 Leishmania tarentolae as a novel live vector  
Although live recombinant vectors (bacterial or viral recombinant vectors) have been known 
to develop new vaccine strategies against pathogens (e.g., HIV-1), their use as vaccine 
candidates in human is delayed due to problems related to pre-existing immunity, 
inefficient antigen delivery or presentation and toxicity issues. Therefore, it is necessary to 
develop new live-vaccine vectors that are able to enhance antigen presentation and elicit 
potent immune responses without the risk of developing disease in humans. Recently, a 
lizard parasitic protozoan that is not pathogenic to humans, Leishmania tarentolae (L. 
tarentolae), has been used as a candidate vaccine against visceral leishmaniasis [Breton et al., 
2005], and HIV-1 [Breton et al., 2007]. L. tarentolae can elicit T-cell proliferation and the 
production of gamma interferon (IFN-Ǆ), skewing the T-cell response towards a Th1-cell 
phenotype, and it provides inflammatory responses for the APC and acts as an 
immunostimulatory adjuvant. Unlike other pathogenic Leishmania strains, L.tarentolae lacks 
the potential to replicate within the targeted APCs and is eliminated after several days from 
the infected murine host [Breton et al., 2005; Breton et al., 2007]. It has been shown that a 
single intraperitoneal injection of L. tarentolae could elicit a protective immune response 
against infectious challenge with L. donovani in susceptible BALB/c mice [Breton et al., 
2005]. Similarly, a single intraperitoneal administration of the A2-recombinant L. tarentolae 
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strain could induce high levels of IFN-gamma and protect BALB/c mice against L. infantum 
challenge [Mizbani et al., 2009]. Interestingly, a recombinant L. tarentolae vaccine expressing 
high levels of full-length HIV-1 Gag elicited cell-mediated immunity in mice model and 
decreased HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection 
[Breton et al., 2007]. These data suggest that the use of L. tarentolae as a live vaccine vector 
may represent a promising approach for improving immunity and safety of candidate live 
vaccines against Leishmania infections and likely other intracellular pathogens for which T-
cell mediated responses are critical for the development of protective immunity [Breitling et 
al, 2002; Breton et al., 2005].   
9.2 Yeast as an efficient tool in vaccine development  
Recent studies have indicated that yeast cell wall components possess multiple adjuvant 
properties. Interactions between yeast and DCs result in DC maturation, and whole 
recombinant yeast internalized by DCs can deliver heterologous antigens to both MHC class I 
and class II pathways and induce potent cell-mediated immunity [Capilla et al., 2009; Bian et 
al., 2010; Haller et al., 2007].  Vaccination with Saccharomyces cerevisiae (S.cerevisiae) expressing 
tumor-associated antigens can induce antigen-specific T-cell responses and protect animals 
against tumor challenge. In addition, S. cerevisiae is inherently nonpathogenic and heat-killed 
recombinant S. cerevisiae shows no toxicity in clinical studies. Yeast can be easily engineered to 
express multiple antigens and the inherent adjuvant properties of S. cerevisiae avoid the need 
for additional adjuvants. These characteristics make S. cerevisiae a potential vaccine vehicle for 
cancer and infectious diseases [Capilla et al., 2009; Bian et al., 2010; Haller et al., 2007].  There 
are some limitations and drawback in S. cerevisiae expression systems. For example, S. cerevisiae 
has a tendency to hyperglycosylate recombinant proteins, N-linked carbohydrate chains are 
terminated with alpha-1, 3-linked mannose residues which is considered to be allergenic. 
Other restriction is that the varieties of carbon sources that can be utilized by this species are 
limited [Bian et al., 2010]. Currently, two other species including Hansenula polymorpha and 
Pichia pastoris belonging to the Saccharomycetaceae family, could potentially overcome the 
described limitations of S. cerevisiae [Bazan et al., 2009; Bian et al., 2010]. On the other hand, 
these two species are broadly used as industrial platforms for heterologous protein  
production [Maleki et al., 2010; Bian et al., 2010].  
10. Conclusion  
A number of methods have been and are being invented for the efficient and safe delivery of 
therapeutic DNA. The perspectives and hopes that are associated with gene therapy support 
research in this field of molecular biology. Although, clinical trials have already started, 
there are still various limitations that must be solved before routine clinical use. The major 
aim in gene therapy is to develop efficient, non-toxic gene carriers that can encapsulate and 
deliver foreign genetic materials into specific cell types including cancerous cells. Both viral 
and non-viral vectors were developed and evaluated for delivering therapeutic genes into 
cancer cells. Many viruses such as retrovirus, adenovirus, herpes simplex virus, adeno-associated 
virus and pox virus have been modified to eliminate their toxicity and maintain their high 
gene transfer capability. Due to the limitations correlated to viral vectors, non-viral vectors 
have been further focused as an alternative in delivery systems. The main non-viral vectors 
include cationic polymers, cationic peptides and cationic liposomes. Currently, many 
modifications to the current delivery systems and novel carrier systems have been 
www.intechopen.com
 
Non-Viral Gene Therapy 
 
46
developed to optimize the transfection efficiency. Furthermore, the route of immunization 
can influence the outcome of the immune response through altering the interaction between 
the vaccine and different APCs at the site of injection. Hence, the routes of administration 
and formulation of DNA clearly affect the therapeutic response by altering immune 
pathway. Among the commonly used methods of DNA vaccination, the highest efficacy was 
achieved after in vivo electroporation and gene gun delivery. However, it is critical to further 
analyze the results of ongoing clinical trials, specifically, in the aspect of their success or 
failure of certain delivery methodologies for gene therapies.  
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